New scan could catch lung disease before symptoms start
NCT ID NCT05417776
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a special PET scan that uses a radioactive tracer to find collagen buildup in the lungs, a sign of early scarring. Researchers will scan 30 people, including relatives of patients with pulmonary fibrosis and those with early lung abnormalities. The goal is to see if this scan can detect interstitial lung disease sooner than current methods.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- [68Ga]CBP8 (a radioactive tracer) and Dotarem (an MRI contrast agent)
- What this could lead to
- If successful, this imaging method could help detect lung scarring earlier, allowing for timely treatment and better outcomes.
- What could go wrong
- This is a small, early-phase study focused on imaging, not treatment. The tracer may not reliably distinguish early disease from normal tissue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2022
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Group 1: First degree relatives of a family member with pulmonary fibrosis (n=8) * Age greater than 40 years * Have the ability to give written informed consent * First degree relative of a family member with pulmonary fibrosis * No known history of interstitial lung disease * No tobacco use within the prior 6 months. Group 2: Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) (n=22) * Age greater than 40 years * Have the ability to give written informed consent * ILAs or early ILD (defined by presence of reticular markings and / or traction bronchiectasis but absence of a definite UIP pattern) * No tobacco use within the prior 6 months. Exclusion criteria: * Electrical implants such as cardiac pacemaker or perfusion pump * Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants ferromagnetic objects such as jewelry or metal clips in clothing * Historical eGFR of less than 30 mL/min/1.73 m2 * Pregnant or breastfeeding (a negative quantitative serum hCG pregnancy test is required for females having child-bearing potential before the subject can participate) * Claustrophobic reactions * Research-related radiation exposure exceeds current Radiology Department guidelines (i.e. 50 mSv in the prior 12 months) * Unable to lie comfortably on a bed inside the MR-PET * BMI \> 33 (limit of the PET-MRI table) * Determined by the investigator(s) to be clinically unsuitable for the study (e.g. based on screening visit and/or during study procedures) * Pneumonia or other acute respiratory illness within 6 weeks of study entry * Parenchymal lung disease except for ILD/ILAs or emphysema * Acute exacerbation of ILD within the prior 6 months * VATS within the prior 6 months * Prior radiation therapy to the thorax * Known allergy to gadolinium.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Interstitial lung disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- Patients and families build a living database of pulmonary fibrosis
- Can better training get doctors to talk about what matters most to dying veterans?
- Inhaled xenon gas could reveal hidden lung vessel disease without catheter
- Radioactive tracer aims to light up hidden lung scarring
- Inhaled drug aims to ease dangerous lung blood pressure in scarred lungs